RIPK1-IN-38
RIPK1-IN-38 is an orally active RIPK1 inhibitor with an IC50 value of 27 nM. RIPK1-IN-38 can inhibit the phosphorylation of RIPK1 and its downstream signaling molecules RIPK3 and MLKL. RIPK1-IN-38 exhibits anti-necroptotic activity. RIPK1-IN-38 has excellent anti-inflammatory efficacy in both the SIRS model and GVHD model. RIPK1-IN-38 can be used for the research of inflammatory and immune-related diseases[1].
Product Specifications
CAS Number
3092834-30-2
UNSPSC
12352005
Target
Interleukin Related; Lactate Dehydrogenase; Mixed Lineage Kinase; Necroptosis; RIP kinase
Related Pathways
Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease
Field of Research
Inflammation/Immunology
Smiles
O=C(N[C@@H](C)C1=CC=C(F)C=C1)C2=C3N(C=CC(C4=CC5=C(N=C(NC(C6CC6)=O)S5)C=C4)=C3)N=C2
Molecular Formula
C27H22FN5O2S
Molecular Weight
499.56
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-6; RIPK1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human IgG Immunoglobulin (IG266), CF488A conjugate, 0.1mg/mL
CD106 / VCAM1 (B-K9), CF640R conjugate, 0.1mg/mL
Beta-2-Microglobulin (B2M) (B2M/1118), CF740 conjugate, 0.1mg/mL
N-Cadherin / Cadherin-2 / CD325 (NCAD) (CDH2/1573), CF647 conjugate, 0.1mg/mL
